Orejas Rodríguez-Arango G, Málaga Guerrero S, Santos Rodríguez F, Martínez Gonzáles I, Rodríguez Fernández L M, Rey Galán C
Sección de Nefrología Pediátrica, Hospital Universitario Nuestra Señora de Covadonga, Facultad de Medicina, Oviedo, Asturias.
An Esp Pediatr. 1990 Oct;33(4):335-8.
We have calculated the mean annual cost (MAC) referred to 1,988 pesetas derived from the treatment and surveillance of 15 patients diagnosed of non terminal chronic renal failure (NT-CRF). The patients were aged between 1 month and 12 years at the moment of diagnosis and they were followed-up for five years at least. We have differentiated among costs from hospitalization, pharmacological treatment and outpatient control which were respectively 455,400, 47,798 and 57,917 pesetas/patient year. The costs from hospitalization decreased progressively every year after diagnosis being of 21,211 pesetas/patient year at the 5th year from diagnosis. The 30.1% of pharmacological treatment costs were due to the use of alkalines, 23.4% to phosphorus quelants (calcic carbonate mainly) and 27.3% to the active forms of vitamin D3. The outpatient surveillance costs corresponded 24,000 pesetas/year to staff expenses, 27,492 pesetas/year to laboratory work-up and 6,424 pesetas/year to radiological examination. We conclude that the total MAC for children with NT-CRF eas 561,115 pesetas/patient being the hospitalizations costs the most important concept (81.2%), followed by ambulatory care (10.3% and drug treatment (8.5%).
我们计算了15例非终末期慢性肾衰竭（NT-CRF）确诊患者治疗和监测的年均成本（MAC），以1988比塞塔为参照。诊断时患者年龄在1个月至12岁之间，至少随访了5年。我们区分了住院、药物治疗和门诊检查的费用，分别为455,400比塞塔/患者年、47,798比塞塔/患者年和57,917比塞塔/患者年。诊断后每年住院费用逐渐降低，诊断后第5年为21,211比塞塔/患者年。药物治疗费用的30.1%用于碱性药物，23.4%用于磷螯合剂（主要是碳酸钙），27.3%用于活性维生素D3。门诊监测费用中，每年员工费用为24,000比塞塔，实验室检查为27,492比塞塔，放射检查为6,424比塞塔。我们得出结论，NT-CRF患儿的总MAC为561,115比塞塔/患者，其中住院费用是最重要的部分（81.2%），其次是门诊护理（10.3%）和药物治疗（8.5%）。
